Development of a Gene and Oligonucleotide Delivery System
Development of a Gene and Oligonucleotide Delivery System
批准号:
8981573
负责人:
Gary Fujii
金额:
$32.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2016-12-31
关键词:
Antisense OligonucleotidesBindingBiological AssayBreast Cancer CellCapsidCapsid ProteinsCell LineCell membraneCellsCellular AssayCytoplasmDNADevelopmentEffectivenessEpidermal Growth FactorEpidermal Growth Factor ReceptorFluorescence MicroscopyGene DeliveryGene TargetingGenesGeneticGenetic MedicineHealthcareHousingHypoxiaHypoxia Inducible FactorIn VitroIncubatedIonic StrengthsLabelLengthLigandsLipid BilayersLipidsLiteratureMDA MB 231Mammalian CellMeasurementMedicalMedicineMethodsModelingMono-SOligonucleotidesOrganOxygenPhospholipidsPlant VirusesPlantsPolymersProductionProteinsRNARelative (related person)Small Interfering RNASystemTechnologyTestingTissuesToxic effectVascular Endothelial Growth FactorsViralVirusVirus-like particleWorkangiogenesisbasecancer cellcowpea chlorotic mottle virusimmunogenicityinterestmalignant breast neoplasmnanoparticlenovelnovel strategiesparticlepublic health relevancereconstitutionresearch studyself assemblytargeted deliverytumoruptakevector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The knockdown of targeted genes by anti-sense oligonucleotides (ODNS) and genetic medicines (collectively, G-MEDS) holds promise for a variety of therapies. The delivery of effective quantities of ODNS to specific cells, however, has proved to be challenging. We propose here a novel approach to ODN delivery that involves enveloped virus-like-particles (EVLPs). These delivery agents are prepared by the in vitro self- assembly of pure G-MEDS and pure viral capsid protein (CP) into virus-like nanoparticles particles (VLPs). The capsid protects the contents yet, as we have demonstrated, is capable of giving up its contents in the cytoplasm of mammalian cells. The particles, which are highly mono-disperse, are then enveloped by lipid bilayers that can suppress the immunogenicity of the VLPs and are capable of being functionalized for targeting and uptake by mammalian cells of interest. In preliminary experiments, we have demonstrated our ability to prepare EVLPs using the CP of the cowpea chlorotic mottle virus and a model antisense ODN for vascular endothelial growth factor (VEGF), a protein over-expressed in many cancer cells to stimulate angiogenesis a facilitate tumor survival under low- oxygen conditions. We propose to optimize the assembly and to functionalize the lipid bilayers with epidermal growth factor (EGF), which binds the EGF receptor that is over-expressed on cancer cells, especially those of breast cancer. The effectiveness of the EVLP will be demonstrated by assaying the reduction in the secretion of VEGF in cultured breast cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
-
批准号:10385208
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
-
批准号:10576383
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
Niclosamide Formulations for the Treatment of Influenza Infections
-
批准号:10385194
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10432112
-
项目类别:
-
资助金额:$103.18万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10252528
-
项目类别:
-
资助金额:$95.69万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10668735
-
项目类别:
-
资助金额:$6.72万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10672648
-
项目类别:
-
资助金额:$11.34万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Optimization of VesiVax® Lipidated Tucaresol Formulations
-
批准号:9131908
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:Gary Fujii
-
依托单位:
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
-
批准号:8981051
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:Gary Fujii
-
依托单位:
Design and Engineering of Nanoparticulate Universal Vaccines
-
批准号:8978668
-
项目类别:
-
资助金额:$29.03万
-
财政年份:2015
-
负责人:Gary Fujii
-
依托单位:
Engineering of a Novel CDN Nanoparticle Platform
-
批准号:8782396
-
项目类别:
-
资助金额:$24.59万
-
财政年份:2014
-
负责人:Gary Fujii
-
依托单位:
Novel VLP Adjuvant based on the VesiVax system
-
批准号:8524930
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Novel VLP Adjuvant based on the VesiVax system
-
批准号:8720689
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Development of VesiVax Carbohydrate Conjugation Chemistry
-
批准号:8593016
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Liposomal Nicotine Vaccine Development
-
批准号:8211742
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2011
-
负责人:Gary Fujii
-
依托单位:
ENDPOINTS FOR CORRELATING PROTECTIVE IMMUNITY IN RESPONSE TO INFLUENZA
-
批准号:8357370
-
项目类别:
-
资助金额:$10.48万
-
财政年份:2011
-
负责人:Gary Fujii
-
依托单位:
Genital Herpes Vaccine Discovery
-
批准号:8068125
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2010
-
负责人:Gary Fujii
-
依托单位:
Surrogate endpoints for correlating protective immunity in response to influenza
-
批准号:7608534
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2009
-
负责人:Gary Fujii
-
依托单位:
Thermal Targeting of Antimicrobial Drugs to Sites of Infection
-
批准号:7481628
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Gary Fujii
-
依托单位:
Liposomal Adjuvant for Vaccine Development
-
批准号:7393355
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Gary Fujii
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: